便秘:治療薬開発パイプライン分析

【英語タイトル】Constipation - Pipeline Review, H1 2018

Global Markets Directが出版した調査資料(GMDHC10076IDB)・商品コード:GMDHC10076IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2018年1月18日
・ページ数:117
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における便秘の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・便秘の概要
・便秘治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・便秘パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・便秘治療薬開発に取り組んでいる企業:企業別製品パイプライン
・便秘治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Constipation – Pipeline Review, H1 2018

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Constipation – Pipeline Review, H1 2018, provides an overview of the Constipation (Gastrointestinal) pipeline landscape.

Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Constipation – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 4, 9, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Constipation (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Constipation (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Constipation (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Constipation (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Constipation – Overview
Constipation – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Constipation – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Constipation – Companies Involved in Therapeutics Development
Albireo Pharma Inc
Allergan Plc
Ardelyx Inc
Astellas Pharma Inc
Braintree Laboratories Inc
Dong-A ST Co Ltd
EA Pharma Co Ltd
Ironwood Pharmaceuticals Inc
Johnson & Johnson
NGM Biopharmaceuticals Inc
RaQualia Pharma Inc
Sanwa Kagaku Kenkyusho Co Ltd
SK Biopharmaceuticals Co Ltd
Sucampo Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Synergy Pharmaceuticals Inc
Synthetic Biologics Inc
Vanda Pharmaceuticals Inc
Yuhan Corp
Zensun (Shanghai) Sci & Tech Co Ltd
Constipation – Drug Profiles
5-BIOP – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AJG-555 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-7663 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Irritable Bowel Syndrome with Constipation – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLI-400 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLI-801 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-6886 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSP-6952 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elobixibat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENT-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
J-027 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide DR2 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lovastatin MR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lubiprostone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naronapride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plecanatide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prucalopride succinate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relenopride hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00000010 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SK-1202 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenapanor – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-12852 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZS-06 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Constipation – Dormant Projects
Constipation – Discontinued Products
Constipation – Product Development Milestones
Featured News & Press Releases
Jan 03, 2018: Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C
Dec 19, 2017: Synergy Pharmaceuticals Appoints Troy Hamilton Chief Executive Officer
Nov 27, 2017: Application for Marketing and Manufacturing Approval of Chronic Constipation Treatment AJG555 Was Filed in Japan
Nov 09, 2017: Synergy Pharmaceuticals Provides Update on TRULANCE
Oct 16, 2017: Allergan to Present New Data on Gastrointestinal Drug Candidate Linaclotide at the World Congress of Gastroenterology at ACG 2017
Oct 16, 2017: Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
Oct 12, 2017: Synergy Pharmaceuticals to Highlight New Data for TRULANCE (Plecanatide) at the World Congress of Gastroenterology at American College of Gastroenterology
Oct 11, 2017: Ardelyxs Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018
Sep 28, 2017: Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation
Sep 11, 2017: Astellas Submits Supplemental New Drug Application for Approval of Additional Indication of “Linaclotide” for Patients with Chronic Constipation in Japan
Jun 27, 2017: Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation
Jun 07, 2017: Synergy Pharmaceuticals Announces Acceptance of Supplemental New Drug Application (sNDA) for TRULANCE (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation
May 12, 2017: Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
May 09, 2017: Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide’s Effect on Pain at Digestive Disease Week 2017
May 07, 2017: Synergy Pharmaceuticals to Present TRULANCE (Plecanatide) Phase 3 Data at Digestive Disease Week for the Treatment of Adults with Chronic Idiopathic Constipation with Moderate to Very Severe Bloating
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Constipation, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Constipation - Pipeline by Albireo Pharma Inc, H1 2018
Constipation - Pipeline by Allergan Plc, H1 2018
Constipation - Pipeline by Ardelyx Inc, H1 2018
Constipation - Pipeline by Astellas Pharma Inc, H1 2018
Constipation - Pipeline by Braintree Laboratories Inc, H1 2018
Constipation - Pipeline by Dong-A ST Co Ltd, H1 2018
Constipation - Pipeline by EA Pharma Co Ltd, H1 2018
Constipation - Pipeline by Ironwood Pharmaceuticals Inc, H1 2018
Constipation - Pipeline by Johnson & Johnson, H1 2018
Constipation - Pipeline by NGM Biopharmaceuticals Inc, H1 2018
Constipation - Pipeline by RaQualia Pharma Inc, H1 2018
Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2018
Constipation - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2018
Constipation - Pipeline by Sucampo Pharmaceuticals Inc, H1 2018
Constipation - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018
Constipation - Pipeline by Synergy Pharmaceuticals Inc, H1 2018
Constipation - Pipeline by Synthetic Biologics Inc, H1 2018
Constipation - Pipeline by Vanda Pharmaceuticals Inc, H1 2018
Constipation - Pipeline by Yuhan Corp, H1 2018
Constipation - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2018
Constipation - Dormant Projects, H1 2018
Constipation - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Constipation, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

【レポートのキーワード】

便秘

★調査レポート[便秘:治療薬開発パイプライン分析] (コード:GMDHC10076IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[便秘:治療薬開発パイプライン分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆